LiquidCell Dx has published research in Nature on LiquidTME, a blood-based assay that profiles the tumor microenvironment and predicts immunotherapy response, potentially offering a noninvasive alternative to tissue biopsy.
NeuroVision Imaging has acquired Durin Life Sciences, combining blood-based biomarker tests with retinal imaging and telehealth to advance early detection of Alzheimer’s and Parkinson’s diseases.
The FDA has granted Breakthrough Device designation to PreludeDx’s AidaBREAST assay, which uses multi-omic data and AI to assess recurrence risk and radiation therapy benefit in early-stage invasive breast cancer.
HistoIndex has partnered with Houston Research Institute and Knowledge Research Center to expand access to AI-driven digital pathology for liver disease diagnostics in Texas and California.
Scopio Labs’ Full-Field Bone Marrow Aspirate Application has received EU IVDR certification, enabling high-throughput digital imaging at 100x resolution to support regulated hematology workflows on the X100 and X100HT platforms.
Researchers at Mass General Brigham identified 16 routine lab markers, including cholesterol and glucose, linked to PTSD’s physical effects, suggesting standard tests could aid in assessing the disorder’s multi-organ impact.
The ViaPlex 2-Color Cell Barcoding Kit uses two reactive fluorescent dyes to combine up to 15 distinct cell populations in one tube, reducing reagent use and run time.
The test allows for simultaneous detection of multiple viruses on a sample-to-answer platform designed for immunocompromised patients.
Mayo Clinic researchers have developed a blood test that detected 93% of germ cell tumors—including cases missed by standard markers.
AOA Dx presented data at AACR 2026 supporting its AKRIVIS GD Test System, a multi-omic, blood-based assay for early ovarian cancer detection in symptomatic women, reporting an AUC of 0.92 in clinical controls.
Early use of rapid sepsis diagnostics could prevent 36,200 deaths and 84,400 sepsis cases annually in the US, according to a multi-country health economic analysis announced by bioMérieux and conducted by the Office of Health Economics.
Researchers have developed a urine-based liquid biopsy test that filters age-related mutations, potentially enabling more accurate prediction of bladder cancer recurrence and guiding immunotherapy decisions.
The cobas liat system delivers PCR results in 15 minutes, detecting and differentiating between three Bordetella pathogens including whooping cough.
A rapid urine test identified effective UTI antibiotics in an average of 5.85 hours, matching standard lab accuracy in a University of Reading study published in the Journal of Antimicrobial Chemotherapy.